DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
3.735
-0.025 (-0.66%)
Apr 1, 2025, 3:59 PM EDT - Market closed

DiaMedica Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
7.628.166.164.884.49
Upgrade
Research & Development
19.0613.117.848.778.21
Upgrade
Operating Expenses
26.6821.271413.6512.7
Upgrade
Operating Income
-26.68-21.27-14-13.65-12.7
Upgrade
Interest & Investment Income
2.271.930.35--
Upgrade
Other Non Operating Income (Expenses)
---0.080.43
Upgrade
EBT Excluding Unusual Items
-24.41-19.34-13.65-13.56-12.27
Upgrade
Pretax Income
-24.41-19.34-13.65-13.56-12.27
Upgrade
Income Tax Expense
0.030.040.030.030.03
Upgrade
Net Income
-24.44-19.38-13.68-13.59-12.29
Upgrade
Net Income to Common
-24.44-19.38-13.68-13.59-12.29
Upgrade
Shares Outstanding (Basic)
4033262116
Upgrade
Shares Outstanding (Diluted)
4033262116
Upgrade
Shares Change (YoY)
24.07%23.16%27.29%32.48%30.80%
Upgrade
EPS (Basic)
-0.60-0.60-0.52-0.65-0.78
Upgrade
EPS (Diluted)
-0.60-0.60-0.52-0.65-0.78
Upgrade
Free Cash Flow
-22.1-18.75-11.59-12.27-9.23
Upgrade
Free Cash Flow Per Share
-0.55-0.58-0.44-0.59-0.59
Upgrade
EBITDA
-26.64-21.24-13.98-13.62-12.68
Upgrade
D&A For EBITDA
0.040.030.030.020.02
Upgrade
EBIT
-26.68-21.27-14-13.65-12.7
Upgrade
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q